Medi-Tate

Company Overview

Snapshot

Founded in February 2007 by Ido Kilemnik, Medi-Tate operated with 1-10 employees. The company secured funding across 3 rounds from 3 investors, culminating in its acquisition by Olympus Corporation in February 2021.

Business overview

Medi-Tate is a Health Tech & Life Sciences company focused on developing innovative solutions for treating diseases of the urethra and prostate. Its core product, the iTind system, is a minimally invasive device designed to alleviate symptoms of benign prostate hyperplasia (BPH) by reshaping the prostate. The device is deployed for five days, offering a therapeutic effect without permanent implants or catheters, and is suitable for various clinical settings. Medi-Tate serves the healthcare market, targeting patients and providers in regions including the European Union, Canada, Hong Kong, and Israel.

Strategic signal

In June 2022, Olympus announced the first commercial treatments of Benign Prostatic Hyperplasia (BPH) in Canada using Medi-Tate's minimally invasive iTind device. This expansion into the Canadian market demonstrates continued post-acquisition growth and market penetration for the iTind system, signaling strong commercial traction and broader adoption of its technology within the urology sector.

Company Intelligence Q&A

When was Medi-Tate acquired and by whom?

Medi-Tate was acquired by Olympus Corporation in February 2021.

What was the key regulatory approval for Medi-Tate's iTind system in April 2020?

In April 2020, Medi-Tate received an FDA De Novo classification for its iTind system.

What were the findings of the long-term efficacy study for the iTind procedure in May 2022?

In May 2022, study results announced by Olympus showed long-term efficacy and durability of the iTind procedure for treating BPH symptoms for up to 6.6 years, with minimal complications.

What strategic partnership did Medi-Tate form in November 2018?

In November 2018, Medi-Tate received an investment from Olympus Corporation, which also secured distribution rights for Medi-Tate's products in Japan and an option to acquire the company.

What was a significant market expansion event for the iTind device in June 2022?

In June 2022, the first commercial treatment procedures using the minimally invasive iTind device for BPH were performed in Canada, marking a significant expansion for the product.